What is the 13F Pro Quality Score for DHR?

13F Pro ranks DANAHER CORP /DE/ (DHR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DHR's current score at https://13fpro.ai/company/DHR (free sign-up required for the full ranking).

Which hedge funds own the most DHR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of DHR include BlackRock,, VANGUARD CAPITAL MANAGEMENT, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/DHR as soon as new 13F filings post.

Where does 13F Pro source DHR data?

All DANAHER CORP /DE/ fundamentals and ownership data come directly from SEC EDGAR. DANAHER CORP /DE/ files with the SEC under CIK 313616. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DHR in?

DANAHER CORP /DE/ (DHR) is classified in the Technology sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/technology.

What drives DHR's revenue?

Per DANAHER CORP /DE/'s latest 10-Q filed with the SEC on 2026-07-21, the biggest revenue drivers are: Diagnostics ($2.5B, +7.0% YoY); Biotechnology ($1.9B, +4.0% YoY); Life Sciences ($1.9B, +5.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/DHR.

What are DHR's largest expenses?

DANAHER CORP /DE/'s latest 10-Q reports these as the largest expense items: Cost of sales ($2.7B, +9.9% YoY); Selling, general and administrative expenses ($2.1B, -12.2% YoY); Research and development expenses ($412M, +2.2% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 26, 2026).

How often is DHR research updated on 13F Pro?

DHR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

DANAHER CORP /DE/(DHR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Technology →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 313616 DHR stock profile & AI dashboard →

13F Pro Quality Score

64.8/100

Rank #521 of 2,961 stocksTOP 25%

View Technology peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

35.3/100

Profitability

76.3/100

Balance Sheet

67.9/100

Earnings Quality

63.0/100

Free Cash Flow

75.2/100

Institutional Flow

69.1/100

Revenue Scale

94.0/100

Dilution Risk

51.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why DHR Scores 65/100

exact factor attribution · 2026-09-11

DHR's composite is driven by scale and profitability, held back by revenue growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.6 pts

94th pct

Profitability

+3.9 pts

76th pct

Free cash flow

+3.8 pts

75th pct

Capital efficiency

+1.8 pts

68th pct

Earnings quality

+1.3 pts

63th pct

Institutional flow

+0.9 pts

69th pct

Shareholder dilution

+0.1 pts

52th pct

Earnings growth

-0.7 pts

35th pct

Revenue growth

-2.9 pts

35th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

DHR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for DANAHER CORP /DE/ (DHR), a Technology sector company. 13F Pro's AI-powered ranking engine scores DHR at 64.8/100 on a 32-signal composite quality model, placing it at rank #521 of 2,961 stocks — the top 25% of the AI-ranked universe. DHR scores in the top quartile across revenue scale (94.0), profitability (76.3), free cash flow (75.2). Areas of concern include revenue growth (35.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), DANAHER CORP /DE/ reports quarterly revenue of $6.3B, net income of $870.0M, an operating margin of 18.0%. Top institutional holders of DHR by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, FMR, based on the most recent SEC filings. DHR trades on the NYSE exchange and files with the SEC under CIK 313616. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DHR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DANAHER CORP /DE/ directly from SEC EDGAR. DANAHER CORP /DE/'s 13F Pro composite quality score has ranged between 60 and 82 since 2021, currently 64.8 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about DANAHER CORP /DE/

Quirks, history, and lore behind DHR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. industrial-technology conglomerate · large-cap · listed on the NYSE · incorporated in Delaware and headquartered near Washington, DC.
2
The Numbers
Annual revenue in the range of $30 billion, built almost entirely through acquisitions — the company has swallowed well over 400 businesses since the 1980s.
3
The History
Founded in the mid-1980s by two brothers, it transformed from a humble real-estate investment trust into a precision-instruments and diagnostics giant through relentless deal-making.
4
The Secret
Its real competitive edge is a proprietary lean-manufacturing system — borrowed and refined from the Toyota Production System — that it installs in every company it buys to squeeze out waste and boost margins.
5
The Lore
It spun off its slower-growth industrial businesses in 2016 as Fortive, then spun off its dental segment as Envista in 2019 — shedding units like a snake sheds skin to stay focused on higher-margin science tools.
6
The Giveaway
Its brands include Beckman Coulter, Hach, and Cepheid — making the water you drink cleaner and the blood tests at your doctor's office more accurate, all under one DHR-tickered roof.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving DHR's Business? Latest 10-Q Breakdown

✓ 17/17 datapoints verified

AI-extracted from DANAHER CORP /DE/'s 10-Q filed 2026-07-21 — Q2 FY2026 (quarter ended June 26, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 revenue grew 5.5% YoY to $6.3B, driven by 3.0% core sales growth and the Masimo acquisition; operating margin expanded 520 bps to 18.0% despite $74M in acquisition-related charges.

Biggest Revenue Drivers

Diagnostics$2.5B+7.0% YoY

Increased by Masimo Acquisition contribution and higher clinical diagnostics demand, partially offset by lower respiratory test sales.

Biotechnology$1.9B+4.0% YoY

Increased core sales driven by higher consumables and equipment sales in bioprocessing and discovery and medical businesses.

Biggest Revenue Drivers

Total revenue: $6.3B+5.5% YoY

Diagnostics$2.5B+7.0% YoY

Increased by Masimo Acquisition contribution and higher clinical diagnostics demand, partially offset by lower respiratory test sales.

Biotechnology$1.9B+4.0% YoY

Increased core sales driven by higher consumables and equipment sales in bioprocessing and discovery and medical businesses.

Life Sciences$1.9B+5.5% YoY

Increased core sales primarily driven by higher consumables demand and to a lesser extent higher equipment demand, particularly in filtration and life science instruments.

Largest Expense Items

Cost of sales$2.7B+9.9% YoY

Increased primarily due to higher sales volumes, acquired businesses, and $46M fair value adjustment to Masimo inventory.

Selling, general and administrative expenses$2.1B-12.2% YoY

Decreased primarily due to absence of $432M trade name impairment charge from Q2 2025, partially offset by Masimo acquisition-related costs and transaction costs of $62M.

Research and development expenses$412M+2.2% YoY

Increased with higher sales, but decreased as percentage of sales to 6.6%.

Margins: Operating margin expanded 520 bps to 18.0% in Q2 2026 from 12.8% in Q2 2025, primarily due to the absence of the $432M Life Sciences trade name impairment recorded in the prior year. Gross profit margin declined 170 bps to 57.6% due to product mix and the $46M inventory fair value adjustment related to Masimo, partially offset by operating leverage improvements.

Watch Items from the Filing

Masimo Acquisition integration: $9.8B acquisition closed June 10, 2026; preliminarily recorded $5.0B goodwill with ongoing measurement-period adjustments for fair value allocations and $74M nonrecurring charges in Q2.
Diagnostics segment respiratory testing dependency: Lower respiratory season in H1 2026 drove core sales decline of 1.0% YoY; future results depend on uncontrollable severity levels of influenza.
Foreign currency headwind: FX translation gained 1.0% and 2.0% to Q2 and H1 sales respectively; stronger U.S. dollar relative to euro and other currencies would adversely impact future sales.
China market softness: Core sales declined in Diagnostics and Biotechnology segments due to volume-based procurement program pricing pressures and healthcare reimbursement changes, though moderating.
Masimo litigation contingencies: Inherited $634M jury verdict from Apple patent litigation pending final judgment; multiple other legal proceedings (DOJ investigation, Kiani employment litigation, Willow arbitration) with uncertain outcomes.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$6.3B

Net Income

Q2 2026

$870.0M

Free Cash Flow

Q2 2026

$1.3B

Operating Margin

Q2 2026

18.0%

ROIC

Q2 2026

5.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+2.9% YoY

$24.57BFY 2025

FY22 $26.64BFY23 $23.89BFY24 $23.88BFY25 $24.57B

Net Income

-7.3% YoY

$3.61BFY 2025

FY22 $7.21BFY23 $4.76BFY24 $3.90BFY25 $3.61B

Operating Income

-3.6% YoY

$4.69BFY 2025

FY22 $7.54BFY23 $5.20BFY24 $4.86BFY25 $4.69B

EPS (Diluted)

-4.5% YoY

$5.05FY 2025

FY22 $9.66FY23 $6.38FY24 $5.29FY25 $5.05

Total Assets

+7.6% YoY

$83.46BFY 2025

FY22 $84.35BFY23 $84.49BFY24 $77.54BFY25 $83.46B

Total Debt

+11.6% YoY

$18.42BFY 2025

FY22 $20.27BFY23 $20.10BFY24 $16.51BFY25 $18.42B

Op. Cash Flow

-4.1% YoY

$6.42BFY 2025

FY22 $8.52BFY23 $7.16BFY24 $6.69BFY25 $6.42B

Free Cash Flow

-0.7% YoY

$5.26BFY 2025

FY22 $7.40BFY23 $5.78BFY24 $5.30BFY25 $5.26B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$24.57B +2.9%	$23.88B -0.1%	$23.89B -10.3%	$26.64B +7.4%	$24.80B +11.3%	$22.28B
Net Income	$3.61B -7.3%	$3.90B -18.2%	$4.76B -33.9%	$7.21B +12.1%	$6.43B +76.4%	$3.65B
Operating Income	$4.69B -3.6%	$4.86B -6.5%	$5.20B -31.0%	$7.54B +18.2%	$6.38B +50.7%	$4.23B
EPS (Diluted)	$5.05 -4.5%	$5.29 -17.1%	$6.38 -34.0%	$9.66 +12.2%	$8.61 +76.1%	$4.89
Total Assets	$83.46B +7.6%	$77.54B -8.2%	$84.49B +0.2%	$84.35B +1.4%	$83.18B +9.2%	$76.16B
Total Debt	$18.42B +11.6%	$16.51B -17.8%	$20.10B -0.8%	$20.27B -8.6%	$22.18B +4.6%	$21.21B
Operating Cash Flow	$6.42B -4.1%	$6.69B -6.6%	$7.16B -15.9%	$8.52B +1.9%	$8.36B +34.6%	$6.21B
Free Cash Flow	$5.26B -0.7%	$5.30B -8.4%	$5.78B -21.9%	$7.40B +4.0%	$7.12B +31.4%	$5.42B

Get alerted when DHR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for DANAHER CORP /DE/ including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DHR

BlackRock, Inc.
$10.5B55,084,630 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.9B41,377,076 sh
FMR LLC
$5.6B29,540,895 sh
STATE STREET CORP
$5.4B28,456,019 sh
WELLINGTON MANAGEMENT GROUP LLP
$3.1B16,316,834 sh
Capital International Investors
$3.0B15,504,420 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.7B14,280,335 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.7B14,205,213 sh
JPMORGAN CHASE & CO
$2.3B12,185,400 sh
PRICE T ROWE ASSOCIATES INC /MD/
$2.2B11,450,715 sh

Fund	Value	Shares
BlackRock, Inc.	$10.5B	55,084,630
VANGUARD CAPITAL MANAGEMENT LLC	$7.9B	41,377,076
FMR LLC	$5.6B	29,540,895
STATE STREET CORP	$5.4B	28,456,019
WELLINGTON MANAGEMENT GROUP LLP	$3.1B	16,316,834
Capital International Investors	$3.0B	15,504,420
GEODE CAPITAL MANAGEMENT, LLC	$2.7B	14,280,335
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.7B	14,205,213
JPMORGAN CHASE & CO	$2.3B	12,185,400
PRICE T ROWE ASSOCIATES INC /MD/	$2.2B	11,450,715

Companies Similar to DHR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TMO

THERMO FISHER SCIENTIFIC INC.

AI score

Highly similar · 46 shared holders

Capital Research Global Investors Capital International Investors FLOSSBACH VON STORCH SE

ADP

AUTOMATIC DATA PROCESSING INC

AI score

Very similar · 21 shared holders

Capital Research Global Investors National Pension Service AVIVA PLC

EMR

EMERSON ELECTRIC CO

AI score

Very similar · 20 shared holders

1832 Asset Management L.P.NORDEA INVESTMENT MANAGEMENT AB KING LUTHER CAPITAL MANAGEMENT CORP

TXN

TEXAS INSTRUMENTS INC

AI score

Very similar · 33 shared holders

Capital Research Global Investors Capital International Investors PRIMECAP MANAGEMENT CO/CA/

QCOM

QUALCOMM INC/DE

AI score

Very similar · 22 shared holders

National Pension Service Capital Research Global Investors ROYAL LONDON ASSET MANAGEMENT LTD

VLTO

Veralto Corp

AI score

Very similar · 30 shared holders

T. Rowe Price Investment Management, Inc.Mirova US LLC Swedbank AB

Trane Technologies plc

AI score

Very similar · 27 shared holders

Capital Research Global Investors Capital International Investors NORDEA INVESTMENT MANAGEMENT AB

ROK

ROCKWELL AUTOMATION, INC

AI score

Very similar · 24 shared holders

Holocene Advisors, LP NORDEA INVESTMENT MANAGEMENT AB KING LUTHER CAPITAL MANAGEMENT CORP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Technology Companies

View all Technology →

AGILENT TECHNOLOGIES, INC.

AAOI

APPLIED OPTOELECTRONICS, INC.

AAPL

Apple Inc.

ABNB

Airbnb, Inc.

ACCL

Acco Group Holdings Ltd

ACCS

ACCESS Newswire Inc.

ACFN

ACORN ENERGY, INC.

ACIW

ACI WORLDWIDE, INC.

Put DHR on your watchlist

Track score changes the day DANAHER CORP /DE/ files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DHR a good stock to buy?

13F Pro's AI-powered analysis of DANAHER CORP /DE/ (DHR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DHR are available on the DHR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DHR is classified as a large company.

Which hedge funds own DHR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DHR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DANAHER CORP /DE/'s investment landscape.